8-K Announcements
6Material company update
Jun 3, 2026·SEC
Material company update
Jun 3, 2026·SEC
Material company update
Jun 2, 2026·SEC
Hoth Therapeutics, Inc.(HOTH)Earnings, Financials & Key Ratios
HOTH•NASDAQ
$0.95
Price updated Jun 27, 2026
AboutHoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$12M
- Net Income-$12M-52.3%
- EPS (Diluted)-0.90+29.7%
- ROE-191.4%-91.9%
HOTH Price & Volume
Hoth Therapeutics, Inc. (HOTH) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Future Operational Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding shortfall
"Hoth Therapeutics operates as a pre-revenue biotechnology firm heavily reliant on external academic intellectual property, creating a binary risk profile centered on clinical trial outcomes. The company faces significant financial pressure as its cash position has eroded to $4.0 million in 2026Q1 from $11.3 million in 2025Q1, necessitating potential future equity-based financing. Investors should monitor the sustainability of this licensing-heavy model, as the firm continues to report persistent quarterly operating losses, including a $2.6 million loss in 2026Q1, without a clear path to commercial revenue."
Verdict Logic
the company's cash position has declined by approximately 65% since 2025Q1, suggesting that the current $4.0 million liquidity buffer may be insufficient to support long-term clinical development without further dilution.
HOTH Growth Metrics
Hoth Therapeutics, Inc. (HOTH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM34.68%
Return on Capital
10 Years-226.51%
5 Years-140.75%
3 Years-124.47%
Last Year-170.51%
HOTH Recent Earnings
Hoth Therapeutics, Inc. (HOTH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.17-23.4%
$0.14
Rev
—
—
Q2 2026
Mar 27, 2026Metric
Actual
Est
EPS
$0.16-55.2%
$0.10
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.30+0.0%
$0.30
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.17+37.0%
$0.27
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.17vs $0.14-23.4% | — |
| Q2 2026 | Mar 27, 2026 | $0.16vs $0.10-55.2% | — |
| Q4 2025 | Nov 12, 2025 | $0.30vs $0.30+0.0% | — |
| Q3 2025 | Aug 12, 2025 | $0.17vs $0.27+37.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Hoth Therapeutics, Inc. (HOTH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.95 | $12.58M | -1.05 | — | — | -191.4% | — | |
| $5.41 | $2.8B | -31.82 | 40.34% | -2.58% | -17.08% | — | |
| $2.36 | $259.66K | -0.25 | — | -227.72% | -25.53% | — | |
| $3.73 | $64.48M | -2.78 | — | -1070.26% | — | — | |
| $0.97 | $12.43M | -1.08 | 11.8% | -25.66% | -476.72% | — | |
| $0.66 | $85.54M | -4.13 | -10.02% | -2.03% | -9.41% | — |
Compare HOTH vs Peers
Hoth Therapeutics, Inc. (HOTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HOTH SEC Filings & Documents
Hoth Therapeutics, Inc. (HOTH) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when HOTH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HOTH Frequently Asked Questions
Hoth Therapeutics, Inc. (HOTH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is HOTH profitable?
Hoth Therapeutics, Inc. (HOTH) reported a net loss of $11.7M for fiscal year 2025.
Dividend & Returns
What is HOTH's return on equity?
Hoth Therapeutics, Inc. (HOTH) has a return on equity (ROE) of -191.4%. Negative ROE indicates the company is unprofitable.
What is Hoth Therapeutics, Inc.'s free cash flow?
Hoth Therapeutics, Inc. (HOTH) had negative free cash flow of $10.1M in fiscal year 2025, likely due to heavy capital investments.